T1	Participants 16 95	propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis
T2	Participants 181 375	20 newly diagnosed patients with thyrotoxicosis were randomly selected to receive as sole therapy, either propranolol, 40 mg every 6 hours for 14 days, or nadolol, 80 mg each morning for 14 days
T3	Participants 747 782	patients were in a thyrotoxic state
T4	Participants 1062 1101	symptomatic treatment of thyrotoxicosis
T5	Participants 916 930	thyrotoxicosis
